Ascelia Pharma - Commercial and partnership strategy

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 17 June 2024 at 10:30 AM.

At this event Julie Waras Brogren will elaborate on the commercial strategy for Orviglance and what investors should expect in terms of partnerships.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. Ascelia Pharma develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 6/6-2024 12.34.